---
title: "VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289373738.md"
description: "VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp., debuting on the Nasdaq Capital Market under ticker 'VRXA' on June 11, 2026. The company, focused on next-generation cancer therapies using its BiTAC platform, secured $77.5 million in financing to advance its pipeline of bispecific T-cell engagers and antibody-drug conjugates."
datetime: "2026-06-10T20:15:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289373738.md)
  - [en](https://longbridge.com/en/news/289373738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289373738.md)
---

# VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

The merger between VERAXA Biotech and Voyager Acquisition Corp. has been finalized, with the stock of the newly formed entity, $VRXA, set to start trading on NASDAQ from June 11, 2026.

### Related Stocks

- [VACH.US](https://longbridge.com/en/quote/VACH.US.md)
- [VACHU.US](https://longbridge.com/en/quote/VACHU.US.md)
- [VACHW.US](https://longbridge.com/en/quote/VACHW.US.md)

## Related News & Research

- [Is Dover Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/289608765.md)
- [Why Anthropic's 'safe' Mythos-class model won't answer questions about cancer](https://longbridge.com/en/news/289277338.md)
- [New Talvey Plus Darzalex Faspro Data Demonstrate The Strength Of A Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma](https://longbridge.com/en/news/289663072.md)
- [08:01 ETNew York Proton Center Presents Advances in Proton Therapy Across Multiple Cancers at PTCOG 64](https://longbridge.com/en/news/289461179.md)
- [This AI Tool Could Spot Cancer Years Before Diagnosis— And The FDA Is Taking A Look](https://longbridge.com/en/news/289192227.md)